📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-04 14:46
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Rs 0 Revenue in Q1: Fortis Malar Remains Non-Operational with Rs 34.6 Cr Cash Reserve
Fortis Malar Hospitals reported zero operational revenue for the quarter ended June 30, 2026, as it remains a non-operating entity following its 2024 business divestment. The company recorded a marginal consolidated net profit of Rs 0.09 crore, a significant decline from Rs 4.15 crore in Q1 FY26, which was inflated by a one-time provision reversal of Rs 4.08 crore. With a cash and bank balance of Rs 34.59 crore (representing ~36% of its market cap), the management maintains a 'going concern' status while evaluating restructuring options. The company is currently managing legacy liabilities, including contested medico-legal and tax claims totaling approximately Rs 11.25 crore.
Confidence: HIGH
What changedThe company has completed another quarter with zero revenue, confirming that no new business operations have been initiated since the sale of Malar Hospital to MGM Healthcare.
Why it mattersFortis Malar is effectively a cash shell. Its financial significance lies in its remaining liquidity and its potential as a vehicle for a new business acquisition or merger, balanced against legacy legal liabilities.
Revenue (Q1 FY27): Rs 0.00 crNet Profit (Q1 FY27): Rs 0.09 crCash and Bank Balances: Rs 34.59 crCash to Market Cap Ratio: ~36.4%Contested Medico-legal Claims: Rs 6.49 cr
📅 Short termThe stock is likely to remain range-bound as the results confirm the expected non-operational status; any movement will be driven by restructuring news.
📈 Long termLimited structural significance until a new business model is identified; the company is currently just a custodian of cash and legacy liabilities.
⚠ Risk flags
- Non-operational status
- Lack of business visibility
- Legacy medico-legal and tax liabilities
Key Highlights
Operational revenue remained at Rs 0.00 crore for the quarter ended June 30, 2026.
Cash and bank balances stood at Rs 34.59 crore, providing a liquidity buffer against a market cap of Rs 95 crore.
Consolidated Net Profit fell to Rs 0.09 crore from Rs 4.15 crore in the year-ago quarter.
Contested medico-legal claims are estimated at ~Rs 6.49 crore, with additional tax demands (VAT, GST, Income Tax) totaling ~Rs 4.76 crore.
The Board is currently progressing with the finalization of a corporate restructuring plan in consultation with legal advisors.
👀 What to Watch
Investors should focus exclusively on the 'corporate restructuring plan' timeline and the eventual deployment of the Rs 34.6 crore cash pile, as the company currently has no active business operations.
Fortis Malar Q1 FY27: Zero Revenue Maintained; Cash Reserves Stand at ₹34.59 Cr
Fortis Malar Hospitals remains a non-operational entity following its 2024 business divestment, reporting zero revenue for the quarter ended June 30, 2026. The company reported a marginal net profit of approximately ₹0.17 Cr (EPS ₹0.09), primarily sustained by its cash and bank balances of ₹34.59 Cr. This cash reserve is significant, representing roughly 36% of its ₹95 Cr market capitalization. Management continues to evaluate restructuring options with no immediate visibility on new business operations.
Confidence: HIGH
What changedThe company has transitioned into a cash-rich shell entity following its slump sale to MGM Healthcare, with Q1 FY27 results confirming continued zero operations.
Why it mattersThe company's valuation is currently floor-priced by its cash reserves (₹34.59 Cr) and net worth (₹34 Cr), but it faces legacy legal and tax liabilities totaling over ₹11 Cr.
Cash and Bank Balances: ₹34.59 CrCash vs Market Cap: 36.4%Contested Medico-legal claims: ₹6.49 CrQuarterly Revenue: ₹0.0 CrEPS (Q1 FY27): ₹0.09
📅 Short termThe stock is likely to remain stagnant or track the progress of the restructuring announcement, as there are no operational earnings to drive momentum.
📈 Long termLimited structural significance unless the restructuring plan involves a reverse merger or acquisition of a new operating business.
⚠ Risk flags
- Non-operational status with 100% revenue impact
- Significant legacy legal and tax liabilities (₹11.25 Cr)
- No visibility on new business commencement
Key Highlights
Reported zero operational revenue for Q1 FY27, consistent with its non-operational status since February 2024.
Maintains cash and bank balances of ₹34.59 Cr, which management deems sufficient to meet foreseeable obligations.
Total contested contingent liabilities identified at approximately ₹11.25 Cr, including ₹6.49 Cr in medico-legal claims.
Reported a consolidated EPS of ₹0.09 for the quarter, resulting in a nominal net profit of ~₹0.17 Cr.
Management and Board are currently finalizing a corporate restructuring plan in consultation with legal and financial advisors.
👀 What to Watch
Investors should focus exclusively on the upcoming 'corporate restructuring plan' as the only potential catalyst for value creation, given the lack of active business operations.
